Current Ovarian Cancer Maintenance Strategies and Promising New Developments

Gogineni, Vinaya; Morand, Susan; Staats, Hannah; Royfman, Rachel; Devanaboyina, Monika; Einloth, Katelyn; Dever, Danielle; Stanbery, Laura; Aaron, Phylicia; Manning, Luisa; Walter, Adam; Edelman, Gerald; Dworkin, Lance; Nemunaitis, John

doi:10.7150/jca.49406

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2021; 12(1):38-53. doi:10.7150/jca.49406 This issue Cite

Review

Current Ovarian Cancer Maintenance Strategies and Promising New Developments

Vinaya Gogineni¹, Susan Morand¹, Hannah Staats¹, Rachel Royfman¹, Monika Devanaboyina¹, Katelyn Einloth¹, Danielle Dever¹, Laura Stanbery², Phylicia Aaron², Luisa Manning², Adam Walter³, Gerald Edelman¹, Lance Dworkin¹, John Nemunaitis^2✉

1. University of Toledo Medical Center, Toledo, OH
2. Gradalis, Inc, Carrollton, TX
3. Promedica Health System, Toledo, OH

Citation:

Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J. Current Ovarian Cancer Maintenance Strategies and Promising New Developments. J Cancer 2021; 12(1):38-53. doi:10.7150/jca.49406. https://www.jcancer.org/v12p0038.htm

Other styles

Abstract

While ovarian cancer typically responds well to front line treatment, many patients will relapse within 5 years. Treatment options are less effective at each recurrence highlighting the need for novel maintenance therapies. PolyADP-ribose polymerase (PARP) inhibitors have recently gained approval in ovarian cancer maintenance. Niraparib was approved regardless of BRCA mutation status, however impact on overall survival is limited. Oliparib was approved for BRCA mutant and BRCA wildtype/homologous recombination deficient patients. This review will focus on current frontline ovarian cancer treatment as well molecularly based approaches to ovarian cancer management.

Keywords: ovarian cancer maintenance, HGSOC, ovarian cancer treatment, Vigil

Citation styles

APA

Gogineni, V., Morand, S., Staats, H., Royfman, R., Devanaboyina, M., Einloth, K., Dever, D., Stanbery, L., Aaron, P., Manning, L., Walter, A., Edelman, G., Dworkin, L., Nemunaitis, J. (2021). Current Ovarian Cancer Maintenance Strategies and Promising New Developments. Journal of Cancer, 12(1), 38-53. https://doi.org/10.7150/jca.49406.

ACS

Gogineni, V.; Morand, S.; Staats, H.; Royfman, R.; Devanaboyina, M.; Einloth, K.; Dever, D.; Stanbery, L.; Aaron, P.; Manning, L.; Walter, A.; Edelman, G.; Dworkin, L.; Nemunaitis, J. Current Ovarian Cancer Maintenance Strategies and Promising New Developments. J. Cancer 2021, 12 (1), 38-53. DOI: 10.7150/jca.49406.

NLM

CSE

Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J. 2021. Current Ovarian Cancer Maintenance Strategies and Promising New Developments. J Cancer. 12(1):38-53.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.